Related Experiment Video
Updated: May 17, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Rituximab in critically ill patients
G Dimopoulos1, A Armaganidis, G Poulakou
1Department of Critical Care, Medical School, University of Athens, Attikon University Hospital, Athens, Greece. gdimop@med.uoa.gr
Rituximab is a monoclonal chimeric antibody used in the treatment of CD20-positive B-cell malignancies and rheumatoid arthritis. However, it is used in several other off-label indications including acute graft-versus-host disease. We sought to critically examine the role of rituximab in the treatment of acute graft versus host disease (aGVHD) in critically ill patients and the potential associations with infectious complications in transplant recipients.
Rituximab is a monoclonal chimeric antibody used in the treatment of CD20-positive B-cell malignancies and rheumatoid arthritis. However, it is used in several other off-label indications including acute graft-versus-host disease. We sought to critically examine the role of rituximab in the treatment of acute graft versus host disease (aGVHD) in critically ill patients and the potential associations with infectious complications in transplant recipients.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Continuous Renal Replacement Therapy
Rheumatic Heart Disease IV: Nursing Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)